Artificial insemination market seen nearly doubling by 2035

Market Research Future projects the global artificial insemination market will grow from $2.63 billion in 2025 to $5.98 billion by 2035, driven by infertility rates, livestock genetics demand and new reproductive technologies. North America leads the market now, while cattle, farms and semen freezing remain the biggest segments.

Why it matters: - The market spans both human fertility care and livestock breeding, so growth reflects demand in healthcare and agriculture at the same time. - Rising infertility and pressure to improve herd genetics are expanding use of artificial insemination as a lower-cost, scalable reproductive option. - The forecast points to broader adoption of digital tools, cryopreservation and precision breeding methods across multiple regions and species.

What happened: - Market Research Future said the global artificial insemination market is projected to rise from USD 2,632.16 million in 2025 to USD 5,979.93 million by 2035. - The forecast implies a compound annual growth rate of 8.62% during 2026-2035. - The market base was estimated at USD 2,397.98 million in 2024. - The report was published Aug. 27, 2026.

The details: - The report ties growth to three main forces: higher infertility prevalence, stronger livestock productivity needs and advances in reproductive technology. - WHO estimates about 17.5% of the global adult population experiences infertility during their lifetime. - Artificial insemination in cattle accounted for about 64% of the application segment in 2024. - Semen freezing technology accounted for about 47% of the technology segment in 2024. - Frozen semen held the largest product share at 52% in 2024. - Consultation services led the service category with a 44% share in 2024. - Farms made up the largest end-use segment with a 69% share in 2024. - North America led the market in 2024 with more than 50% of global revenue, or about USD 1,198.99 million. - Europe was valued at USD 719.39 million in 2024 and held a 30% share. - The Middle East and Africa market was valued at USD 80.61 million in 2024. - The report said the U.S. recorded 389,993 assisted reproductive technology procedures in the latest reporting year, with more than 97,000 infants born.

Between the lines: - The forecast reflects two demand centers that are moving in parallel: fertility care for people and genetic improvement for livestock. - Strong positions in cattle, farms and freezing technology suggest the market remains anchored in established, high-volume use cases even as newer digital tools emerge. - Corporate activity from Genus PLC, Zoetis Inc. and Merck Animal Health signals that animal health companies are treating reproductive technology as a strategic growth area. - The market still appears moderately fragmented, which leaves room for consolidation, partnerships and regional expansion.

What's next: - The report expects new growth from AI-driven fertility monitoring, mobile artificial insemination services and better genetic testing integration. - It also sees opportunity in home-based insemination kits, online platforms and advanced cryopreservation systems. - North America and Europe are likely to stay major revenue centers, while Asia-Pacific and parts of Africa may offer the fastest expansion as livestock production modernizes. - Genus PLC said it will keep pushing precision breeding through collaborations and R&D investment, while Zoetis and Merck Animal Health continue building digital and portfolio capabilities.

The bottom line: - Artificial insemination is moving from a niche reproductive procedure to a broader platform for fertility access, livestock productivity and genetic optimization.